Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides

Virology Journal

Toshiharu Kamura²  Kyogo Itoh³  Kimio Ushijima²  Satoshi Hattori¹  Tetsuro Sasada³  Shigeki Shichijo³  Nobukazu Komatsu³  Naotake Tsuda²  Kouichiro Kawano⁴  Satoko Matsueda³  Akimasa Fukui² 

[1] Biostatistics Center, Kurume University, Kurume, Japan;Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan;Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan;Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan

关键词: Virus-like particles;    Anti-peptide antibody;    Prophylactic vaccine;    Human papillomavirus;   

Others  :  1153828
DOI  :  10.1186/1743-422X-9-199

 received in 2012-02-22, accepted in 2012-09-11,  发布年份 2012

【 摘 要 】

Background

Persistent infection of human papillomavirus (HPV) types 16 and 18 causes cervical cancer. To better understand immune responses to the prophylactic vaccine, HPV 16/18 L1 virus-like particles (HPV-VLPs), we investigated B cell epitopes of HPV16 L1-derived peptides.

Methods

Sera from mice immunized with HPV-16/18 L1 VLPs were analyzed for their IgG titers against 10 different HPV16 L1-derived peptides (20-mer) that contain human leukocyte antigen (HLA)-class I A-2, A-24 and class II DR.

Results

One 20-mer peptide at positions 300 to 319 was identified as a common B cell epitope in both Balb/c (H-2^d) and C57BL/6 (H-2^b) mice. Mapping analysis showed that the 10-amino-acid sequence at positions 304to 313 was an immunogenic portion. It is of note that the binding capability of this 10-mer peptide to the HLA-A2 and HLA-A24 molecules was confirmed by the HLA class I stabilization assay. In addition, one unique 20-mer was determined as a B cell epitope in each strain.

Conclusions

These results might provide new information for better understanding of immune responses to HPV 16 L1.

【 授权许可】

   
2012 Fukui et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
• [2]Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
• [3]Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
• [4]De Carvalho N, Teixeria J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A: Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
• [5]Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iverson OE, Hernandez-Ailta M: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851.
• [6]Ryding J, Dahlberg L, Wallen-Ohman M, Dilner J: Deletion of a major epitope of human papillomavirus tyle16 virus-like particles. J Gen Virol 2007, 88:792-802.
• [7]Tacchini-Cottier F, Weinkopff T, Launois P: Does T Helper Differentiation Correlate with Resistance or Susceptibility to Infection with L. major? Some Insights From the Murine Model. Front Immunol 2012, 3:32.
• [8]Rammensee GH, Fried T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immnogenetics 1995, 41:178-228.
• [9]Guang Lan Z, Khan AM, Srinivasan KN, August JT, Brusic V: MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res 2005, 33:172-179.
• [10]Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 2004, 10(3):929-937.
• [11]Imanishi T, Akazawa T, Kimura A: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA 1991. Edited by Tsuji K, Aizawa M, Sasazuki T. Oxford Scientific Publications, Oxford; 1992:1065-1220.
• [12]Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N: AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(10):6186-6197.
• [13]Komatsu N, Shichijo S, Nakagawa M, Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004, 64:535-546.
• [14]Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000, 164(5):2565-2574.